Freeman Spogli Institute for International Studies Program on Energy and Sustainable Development Stanford University


People


Mark Holodniy   Download vCard
Professor of Medicine, Stanford University School of Medicine and Stanford Health Policy Associate

AIDS Research Center
VA Palo Alto Health Care System
3801 Miranda Ave. (132)
Palo Alto, California 94304-5107

mark.holodniy@va.gov
(650) 852-3408 (voice)
(650) 858-3978 (fax)


Dr. Holodniy is Professor of Medicine (Infectious Diseases & Geographic Medicine division) at Stanford University. Dr. Holodniy has directed the HIV clinical program and AIDS Research Center at VA Palo Alto Health Care System (VAPAHCS) since 1991. Dr. Holodniy is also a staff member in the VHA Office of Public Health and Environmental Hazards, and as such, directs the Office of Public Health Surveillance & Research. He has also been director of the VAPAHCS clinical molecular pathology laboratory since its establishment in 2000. This laboratory is responsible for HIV and HCV testing (including viral load, genotyping and resistance testing) for all VISN 21 sites. Under his direction, the laboratory is involved in the evaluation and development of therapeutic and diagnostic tests related to HIV and HCV infection. Dr. Holodniy has also overseen the conduct of over 75 clinical and diagnostic device trials at VAPAHCS since 1991. Dr. Holodniy is currently the Acting Director of the VA Cooperative Studies Program Coordinating Center at Palo Alto, which through its 45 staff oversees a portfolio of 7 multicenter VA studies and the VA DNA Bank Genomics Program. He is Co-chairman of VA CSP #512, the Options in Management with Antiretrovirals (OPTIMA) tri-national trial, which is addressing the questions of treatment interruption and mega-antiretroviral regimens in patients with multidrug resistant HIV infection. He is also principal investigator for a VA funded multi-investigator Center grant, investigating translational research questions around HIV and HCV. His research program focuses on HIV and HCV viral evolution, development of drug resistance, clinical trial evaluation of novel antiviral compounds, and evaluation of clinical outcomes thorough assessment of HIV/HCV practice patterns.

Other affiliations
Palo Alto Veterans Affairs Health Care System




News around the web

US Supreme Court hears Stanford v. Roche patent case
The case stemmed from a dispute between Stanford and the biotech company over the right to royalties on several patents that sprung from the work of School of Medicine professor Mark Holodniy. Holodniy's research, which established a method to detect ...
March 1, 2011 in The Stanford Daily

US Supreme Court to hear arguments Feb. 28 in Stanford v. Roche
Stanford scientists, including Mark Holodniy, a professor of medicine specializing in AIDS research, developed the patented process with federal funding. While a research fellow at Stanford, Holodniy visited Cetus Corp. to learn a research technique ...
February 23, 2011 in Stanford Report

Roche Supreme Court case to test Bayh-Dole Act
... sued Roche for royalties on HIV screening kits sold by the company that used technology developed by School of Medicine professor Mark Holodniy.
November 10, 2010 in The Stanford Daily

Supreme Court case is about principle, not revenue, says Etchemendy
The case arose from a dispute between Stanford and Roche over ownership of the patents of HIV test kits. In 1988, Stanford researcher Mark Holodniy signed ...
November 5, 2010 in The Stanford Daily

Supreme Court to hear Stanford-Roche case
School of Medicine professor Mark Holodniy developed the technology behind the kits. As a researcher at the University, patents from his work would normally ...
November 2, 2010 in The Stanford Daily

More news around the web »